Literature DB >> 31715127

Induction of BRCAness in Triple-Negative Breast Cancer by a CDK12/13 Inhibitor Improves Chemotherapy.

Jessica L Hopkins1, Lee Zou2.   

Abstract

In this issue of Cancer Cell, Quereda and colleagues report that a newly developed specific inhibitor of CDK12/13, SR-4835, sensitizes triple-negative breast cancer cells to PARP inhibitors and DNA-damaging chemotherapeutics by reducing expression of the genes in the DNA damage response pathway.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID： 31715127     DOI： 10.1016/j.ccell.2019.10.012

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  3 in total

1.  Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness.

Authors:  Farzaneh Darbeheshti; Sepideh Kadkhoda; Mahsa Keshavarz-Fathi; Sepideh Razi; Afshin Bahramy; Yaser Mansoori; Nima Rezaei
Journal:  BMC Cancer       Date:  2022-06-17       Impact factor: 4.638

Review 2.  PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers.

Authors:  Linjie Luo; Khandan Keyomarsi
Journal:  Expert Opin Investig Drugs       Date:  2022-05-03       Impact factor: 6.498

Review 3.  CDK inhibitors in cancer therapy, an overview of recent development.

Authors:  Mengna Zhang; Lingxian Zhang; Ruoxuan Hei; Xiao Li; Haonan Cai; Xuan Wu; Qiping Zheng; Cheguo Cai
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.